Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 130

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 130
---
 Sub. Aadi has agreed to provide Kaken reasonable opportunity to review drafts of the agreements
to be entered into in connection with the Pre-Closing Restructuring and to consider in good faith any reasonable comments timely submitted by Kaken with respect to such agreements.

Clinical Trial Wind Down

Subject to certain limitations
and conditions set forth in the Divestiture Agreement, Aadi has agreed that it will be financially responsible for the full costs and expenses associated with the wind down of the PRECISION-1 Clinical Trial until the earlier of one year from the
date of completion of the Divestiture for the current FDA expanded access program and upon completion of the FDA expanded access program in accordance with the current protocol, and that it would promptly reimburse Kaken and Aadi Sub for any
reasonable and documented out of pocket costs incurred by Kaken or Aadi Sub in connection with such wind-down after the completion of the Divestiture, subject to prior approval by Aadi of the incurrence of such wind-down costs (such approval not to
be unreasonably withheld, conditioned or delayed).

Transition Services

The Divestiture Agreement provides that between the date of the Divestiture Agreement and the date of the completion of the Divestiture, and thereafter
following the date of the completion of the Divestiture, Aadi and Kaken must negotiate in good faith and use reasonable best efforts to enter into and execute an agreement providing for transition services (which we refer to as the “Transition
Services Agreement”), on such terms as may be mutually agreed by Aadi and Kaken. The parties have agreed that under the Transition Services Agreement, Aadi will make available to Kaken for a period of not less than three months but not more
than six

- 87 -

months following the date of completion of the Divestiture, such services and resources (including the time of certain of its executive management and employees) that in each case Aadi has access
to and are within Aadi’s control, as Kaken may reasonably require in order to be able to conduct and operate the FYARRO Business following the completion of the Divestiture in substantially the same or a similar manner as the manner in which it
was operated prior to the completion of the Divestiture, including without limitation services for or relating to support in terms of existing clinical trials, ongoing restructure/transfer of manufacturing facility under appropriate terms and
conditions and drug pricing compliance, and putting in place any arrangement with respect to the Pre-Closing Restructuring